Literature DB >> 26034111

Health-related quality of life in patients with multiple myeloma--does it matter?

Ann Kristin Kvam1, Anders Waage2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26034111      PMCID： PMC4450614          DOI： 10.3324/haematol.2015.127860

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  16 in total

Review 1.  Quality of life research in oncology. Past achievements and future priorities.

Authors:  N K Aaronson; B E Meyerowitz; M Bard; J R Bloom; F I Fawzy; M Feldstein; D Fink; J C Holland; J E Johnson; J T Lowman
Journal:  Cancer       Date:  1991-02-01       Impact factor: 6.860

2.  Improved long-term survival in multiple myeloma up to the age of 80 years.

Authors:  S Y Kristinsson; W F Anderson; O Landgren
Journal:  Leukemia       Date:  2014-01-14       Impact factor: 11.528

Review 3.  Quality of life and clinical trials.

Authors: 
Journal:  Lancet       Date:  1995-07-01       Impact factor: 79.321

4.  Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Authors:  Lotfi Benboubker; Meletios A Dimopoulos; Angela Dispenzieri; John Catalano; Andrew R Belch; Michele Cavo; Antonello Pinto; Katja Weisel; Heinz Ludwig; Nizar Bahlis; Anne Banos; Mourad Tiab; Michel Delforge; Jamie Cavenagh; Catarina Geraldes; Je-Jung Lee; Christine Chen; Albert Oriol; Javier de la Rubia; Lugui Qiu; Darrell J White; Daniel Binder; Kenneth Anderson; Jean-Paul Fermand; Philippe Moreau; Michel Attal; Robert Knight; Guang Chen; Jason Van Oostendorp; Christian Jacques; Annette Ervin-Haynes; Hervé Avet-Loiseau; Cyrille Hulin; Thierry Facon
Journal:  N Engl J Med       Date:  2014-09-04       Impact factor: 91.245

5.  Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.

Authors:  Michel Delforge; Leonard Minuk; Jean-Claude Eisenmann; Bertrand Arnulf; Letizia Canepa; Alberto Fragasso; Serge Leyvraz; Christian Langer; Yousef Ezaydi; Dan T Vogl; Pilar Giraldo-Castellano; Sung-Soo Yoon; Charles Zarnitsky; Martine Escoffre-Barbe; Bernard Lemieux; Kevin Song; Nizar Jacques Bahlis; Shien Guo; Mara Silva Monzini; Annette Ervin-Haynes; Vanessa Houck; Thierry Facon
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

6.  Review of 1027 patients with newly diagnosed multiple myeloma.

Authors:  Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2003-01       Impact factor: 7.616

Review 7.  Quality-of-life assessment in oncology. Achievements and challenges.

Authors:  Mirjam A G Sprangers
Journal:  Acta Oncol       Date:  2002       Impact factor: 4.089

Review 8.  Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations.

Authors:  Ann Kristin Kvam; Peter Fayers; Marianne Hjermstad; Nina Gulbrandsen; Finn Wisloff
Journal:  Eur J Haematol       Date:  2009-06-25       Impact factor: 2.997

9.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.

Authors: 
Journal:  Health Qual Life Outcomes       Date:  2006-10-11       Impact factor: 3.186

10.  Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial.

Authors:  Meletios A Dimopoulos; Antonio Palumbo; Roman Hajek; Martin Kropff; Maria Teresa Petrucci; Philip Lewis; Stefanie Millar; Jingshan Zhang; Jay Mei; Michel Delforge
Journal:  Leuk Lymphoma       Date:  2013-12-17
View more
  10 in total

1.  A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Authors:  Joseph Mikhael; Paul Richardson; Saad Z Usmani; Noopur Raje; William Bensinger; Chatchada Karanes; Frank Campana; Dheepak Kanagavel; Franck Dubin; Qianying Liu; Dorothée Semiond; Kenneth Anderson
Journal:  Blood       Date:  2019-03-12       Impact factor: 22.113

2.  Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

Authors:  A Keith Stewart; Meletios A Dimopoulos; Tamás Masszi; Ivan Špička; Albert Oriol; Roman Hájek; Laura Rosiñol; David S Siegel; Ruben Niesvizky; Andrzej J Jakubowiak; Jesus F San-Miguel; Heinz Ludwig; Jacqui Buchanan; Kim Cocks; Xinqun Yang; Biao Xing; Naseem Zojwalla; Margaret Tonda; Philippe Moreau; Antonio Palumbo
Journal:  J Clin Oncol       Date:  2016-11-10       Impact factor: 44.544

3.  Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.

Authors:  X Leleu; C Kyriakou; I Vande Broek; P Murphy; P Bacon; P Lewis; H Gilet; B Arnould; M T Petrucci
Journal:  Blood Cancer J       Date:  2017-03-17       Impact factor: 11.037

4.  Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study.

Authors:  Imad Maatouk; Susanne He; Natalia Becker; Manuela Hummel; Stefan Hemmer; Michaela Hillengass; Hartmut Goldschmidt; Mechthild Hartmann; Dieter Schellberg; Wolfgang Herzog; Jens Hillengass
Journal:  BMJ Open       Date:  2018-07-30       Impact factor: 2.692

5.  Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study.

Authors:  Kara-Louise Royle; Walter M Gregory; David A Cairns; Sue E Bell; Gordon Cook; Roger G Owen; Mark T Drayson; Faith E Davies; Graham H Jackson; Gareth J Morgan; J Anthony Child
Journal:  Br J Haematol       Date:  2018-07-09       Impact factor: 6.998

6.  Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data.

Authors:  Katja Weisel; Heinz Ludwig; Achim Rieth; Andrea Lebioda; Hartmut Goldschmidt
Journal:  Qual Life Res       Date:  2019-09-24       Impact factor: 4.147

7.  Health-related quality of life of patients with multiple myeloma: A real-world study in China.

Authors:  Xiaozhe Li; Junru Liu; Meilan Chen; Jingli Gu; Beihui Huang; Dong Zheng; Juan Li
Journal:  Cancer Med       Date:  2020-09-02       Impact factor: 4.452

8.  The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.

Authors:  Don Robinson; Dixie-Lee Esseltine; Antoine Regnault; Juliette Meunier; Kevin Liu; Helgi van de Velde
Journal:  Br J Haematol       Date:  2016-06-05       Impact factor: 6.998

9.  Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma.

Authors:  Imad Maatouk; Susanne He; Manuela Hummel; Stefan Hemmer; Michaela Hillengass; Hartmut Goldschmidt; Mechthild Hartmann; Wolfgang Herzog; Jens Hillengass
Journal:  Blood Cancer J       Date:  2019-01-21       Impact factor: 11.037

10.  Health- Related Quality of Life for Multiple Myeloma Patients with Bone Metastases in Indonesia: A Cross-Sectional Study.

Authors:  Nutrisia Aquariushinta Sayuti; Tri Murti Andayani; Dwi Endarti; Kartika Widayati Taroeno-Hariadi
Journal:  Asian Pac J Cancer Prev       Date:  2019-10-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.